Data Snacks
Featured Data Snacks
Immuno-Oncology Landscape
PD-1/PD-L1 inhibitors continue to dominate the immuno-oncology space, with 5 major players having approved products and 12+ in late-stage development.
Multiple Sclerosis Market Dynamics
The approval of Novartis's Kesimpta introduces a new self-administered anti-CD20 therapy, potentially disrupting the current treatment paradigm.
All Data Snacks
JAK Inhibitor Landscape in Immunology
4 competitors have JAK inhibitors in Phase 3 trials for RA, with potential approvals expected in 2026-2027.
Alzheimer's Treatment Trends
Anti-amyloid antibodies continue to dominate the pipeline, with 5 assets in late-stage development.
Oncology Biomarker Landscape
Analysis of biomarker-driven patient selection strategies across major oncology pipelines.
Regulatory Approval Timelines
Comparative analysis of FDA and EMA approval timelines for oncology drugs over the past 5 years.
Gene Therapy Manufacturing Capacity
Analysis of current and planned manufacturing capacity for gene therapies across major players.
© 2025 CI Agent. All rights reserved.